BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

...priced in June.Two other new NASDAQ listings were also big gainers Friday. Biosimulation modeling company Certara...
...of HK$9.5 billion.Staff Writer Hongjiang Li contributed to this report. Paul Bonanos AbCellera Biologics Inc. 4D Molecular Therapeutics Inc. Certara...
BioCentury | Jun 13, 2019
Company News

Complex generic first to show ‘virtual’ bioequivalence with Certara’s modeling system

...approval of an undisclosed complex generic via the ANDA pathway marks the first use of Certara's...
...physiologically based pharmacokinetic (PBPK) modeling and simulation platform, can demonstrate bioequivalence in silico , which Certara L.P....
...defined duration of time (see "Model Firsts" ). The simulator can also determine first-in-human doses, Certara...
BioCentury | May 17, 2019
Tools & Techniques

Leaning on exosomes, model-informed drug development gets closer to tailoring doses to each patient

...we’re talking about is knowing precisely what we should be giving in advance.” Amin Rostami-Hodjegan, Certara...
...a small portion of the variability between individuals. To address that gap, MIDD software developer Certara L.P....
...genes by sequencing RNA in plasma exosomes. Amin Rostami-Hodjegan, CSO and SVP of R&D at Certara...
BioCentury | May 17, 2019
Company News

Management tracks: AstraZeneca, Certara, Longas

...of oncology at University of Calgary and medical director of the Tom Baker Cancer Centre. Certara L.P....
...drug development company’s board. He succeeds CEO Edmundo Muniz, who will become a board member. Certara...
...according to a CNBC report citing Stoddard. Haven could not be reached for comment. BioCentury Staff AstraZeneca plc Certara L.P. Prevail...
BioCentury | Aug 2, 2018
Tools & Techniques

Model firsts

...more influential, because this is the only way that we can integrate all this information.” Certara L.P....
...software for model-informed drug development and other forms of pharmacology and PK/PD modeling. In 2014, Certara...
...but that doesn’t necessarily lead to any increased desired pharmacology,” said Piet van der Graaf, Certara’s...
BioCentury | Apr 20, 2018
Product Development

Lessons from the ECHO chamber

...the rationale supporting different combinations would also aid decision-making. A new precompetitive consortium launched by Certara L.P....
...most likely to succeed before they enter the clinic. The Immuno-oncology Simulator Consortium is using Certara’s...
...Mentioned Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cancer Research Institute (CRI), New York, N.Y. Certara L.P....
BioCentury | Apr 18, 2018
Translation in Brief

Model combination

...of combination immuno-oncology therapy through in silico modeling. The new Immuno-oncology Simulator Consortium is using Certara’s...
...and have access as it is developed. Piet van der Graaf, VP of QSP at Certara...
...of combination synergy without having a quantitative model like we have.” Piet van der Graaf, Certara...
BioCentury | Mar 31, 2017
Regulation

Stuck in the MIDD-le

...and knowledge, and building scientific consensus. It’s not clear how often the agencies would disagree. Certara L.P....
...FDA generally accepts modeling data for induction, whereas EMA is less likely to do so. Certara...
...receive software licenses and vote on priorities for Certara’s Simcyp Simulator modeling and simulation software. Certara...
BioCentury | Jan 6, 2014
Company News

Certara, Arsenal Capital deal

...Private equity firm Arsenal Capital acquired drug discovery and development software company Certara on Dec. 19...
...on Dec. 19, 2013. James Rothman, who is an operating partner at Arsenal Capital, joined Certara's...
...said financial terms are not disclosed, and Certara declined to disclose its revenues. Last September, Certara...
BioCentury | Sep 16, 2013
Company News

Certara, Critical Path Institute deal

...will help researchers test new tuberculosis (TB) drugs. The model will work in conjunction with Certara's...
...of TB infection. Certara declined to provide financial details, and C-Path could not be reached. Certara L.P....
Items per page:
1 - 10 of 14
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

...priced in June.Two other new NASDAQ listings were also big gainers Friday. Biosimulation modeling company Certara...
...of HK$9.5 billion.Staff Writer Hongjiang Li contributed to this report. Paul Bonanos AbCellera Biologics Inc. 4D Molecular Therapeutics Inc. Certara...
BioCentury | Jun 13, 2019
Company News

Complex generic first to show ‘virtual’ bioequivalence with Certara’s modeling system

...approval of an undisclosed complex generic via the ANDA pathway marks the first use of Certara's...
...physiologically based pharmacokinetic (PBPK) modeling and simulation platform, can demonstrate bioequivalence in silico , which Certara L.P....
...defined duration of time (see "Model Firsts" ). The simulator can also determine first-in-human doses, Certara...
BioCentury | May 17, 2019
Tools & Techniques

Leaning on exosomes, model-informed drug development gets closer to tailoring doses to each patient

...we’re talking about is knowing precisely what we should be giving in advance.” Amin Rostami-Hodjegan, Certara...
...a small portion of the variability between individuals. To address that gap, MIDD software developer Certara L.P....
...genes by sequencing RNA in plasma exosomes. Amin Rostami-Hodjegan, CSO and SVP of R&D at Certara...
BioCentury | May 17, 2019
Company News

Management tracks: AstraZeneca, Certara, Longas

...of oncology at University of Calgary and medical director of the Tom Baker Cancer Centre. Certara L.P....
...drug development company’s board. He succeeds CEO Edmundo Muniz, who will become a board member. Certara...
...according to a CNBC report citing Stoddard. Haven could not be reached for comment. BioCentury Staff AstraZeneca plc Certara L.P. Prevail...
BioCentury | Aug 2, 2018
Tools & Techniques

Model firsts

...more influential, because this is the only way that we can integrate all this information.” Certara L.P....
...software for model-informed drug development and other forms of pharmacology and PK/PD modeling. In 2014, Certara...
...but that doesn’t necessarily lead to any increased desired pharmacology,” said Piet van der Graaf, Certara’s...
BioCentury | Apr 20, 2018
Product Development

Lessons from the ECHO chamber

...the rationale supporting different combinations would also aid decision-making. A new precompetitive consortium launched by Certara L.P....
...most likely to succeed before they enter the clinic. The Immuno-oncology Simulator Consortium is using Certara’s...
...Mentioned Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cancer Research Institute (CRI), New York, N.Y. Certara L.P....
BioCentury | Apr 18, 2018
Translation in Brief

Model combination

...of combination immuno-oncology therapy through in silico modeling. The new Immuno-oncology Simulator Consortium is using Certara’s...
...and have access as it is developed. Piet van der Graaf, VP of QSP at Certara...
...of combination synergy without having a quantitative model like we have.” Piet van der Graaf, Certara...
BioCentury | Mar 31, 2017
Regulation

Stuck in the MIDD-le

...and knowledge, and building scientific consensus. It’s not clear how often the agencies would disagree. Certara L.P....
...FDA generally accepts modeling data for induction, whereas EMA is less likely to do so. Certara...
...receive software licenses and vote on priorities for Certara’s Simcyp Simulator modeling and simulation software. Certara...
BioCentury | Jan 6, 2014
Company News

Certara, Arsenal Capital deal

...Private equity firm Arsenal Capital acquired drug discovery and development software company Certara on Dec. 19...
...on Dec. 19, 2013. James Rothman, who is an operating partner at Arsenal Capital, joined Certara's...
...said financial terms are not disclosed, and Certara declined to disclose its revenues. Last September, Certara...
BioCentury | Sep 16, 2013
Company News

Certara, Critical Path Institute deal

...will help researchers test new tuberculosis (TB) drugs. The model will work in conjunction with Certara's...
...of TB infection. Certara declined to provide financial details, and C-Path could not be reached. Certara L.P....
Items per page:
1 - 10 of 14